Literature DB >> 23850704

Phenotypic screens as a renewed approach for drug discovery.

Wei Zheng1, Natasha Thorne, John C McKew.   

Abstract

The significant reduction in the number of newly approved drugs in the past decade has been partially attributed to failures in discovery and validation of new targets. Evaluation of recently approved new drugs has revealed that the number of approved drugs discovered through phenotypic screens, an original drug screening paradigm, has exceeded those discovered through the molecular target-based approach. Phenotypic screening is thus gaining new momentum in drug discovery with the hope that this approach may revitalize drug discovery and improve the success rate of drug approval through the discovery of viable lead compounds and identification of novel drug targets. Published by Elsevier Ltd.

Entities:  

Mesh:

Year:  2013        PMID: 23850704      PMCID: PMC4531371          DOI: 10.1016/j.drudis.2013.07.001

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  76 in total

Review 1.  Systems biology in drug discovery.

Authors:  Eugene C Butcher; Ellen L Berg; Eric J Kunkel
Journal:  Nat Biotechnol       Date:  2004-10       Impact factor: 54.908

Review 2.  How many drug targets are there?

Authors:  John P Overington; Bissan Al-Lazikani; Andrew L Hopkins
Journal:  Nat Rev Drug Discov       Date:  2006-12       Impact factor: 84.694

3.  The use of high-content screening for the discovery and characterization of compounds that modulate mitotic index and cell cycle progression by differing mechanisms of action.

Authors:  Amy Barabasz; Briana Foley; James C Otto; Anisa Scott; John Rice
Journal:  Assay Drug Dev Technol       Date:  2006-04       Impact factor: 1.738

Review 4.  Origin and evolution of high throughput screening.

Authors:  D A Pereira; J A Williams
Journal:  Br J Pharmacol       Date:  2007-07-02       Impact factor: 8.739

5.  Genomic sciences and the medicine of tomorrow.

Authors:  J Drews
Journal:  Nat Biotechnol       Date:  1996-11       Impact factor: 54.908

Review 6.  Calcium antagonists. History and perspective.

Authors:  D J Triggle
Journal:  Stroke       Date:  1990-12       Impact factor: 7.914

Review 7.  Human disease models in Drosophila melanogaster and the role of the fly in therapeutic drug discovery.

Authors:  Udai Bhan Pandey; Charles D Nichols
Journal:  Pharmacol Rev       Date:  2011-03-17       Impact factor: 25.468

8.  Caenorhabditis elegans MPP+ model of Parkinson's disease for high-throughput drug screenings.

Authors:  Evelyn Braungart; Manfred Gerlach; Peter Riederer; Ralf Baumeister; Marius C Hoener
Journal:  Neurodegener Dis       Date:  2004       Impact factor: 2.977

9.  In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461.

Authors:  M Van Heek; C F France; D S Compton; R L McLeod; N P Yumibe; K B Alton; E J Sybertz; H R Davis
Journal:  J Pharmacol Exp Ther       Date:  1997-10       Impact factor: 4.030

Review 10.  Current status of drug screening and disease modelling in human pluripotent stem cells.

Authors:  Divya Rajamohan; Elena Matsa; Spandan Kalra; James Crutchley; Asha Patel; Vinoj George; Chris Denning
Journal:  Bioessays       Date:  2012-08-08       Impact factor: 4.345

View more
  119 in total

Review 1.  Discovery of novel drug targets and their functions using phenotypic screening of natural products.

Authors:  Junghwa Chang; Ho Jeong Kwon
Journal:  J Ind Microbiol Biotechnol       Date:  2015-09-12       Impact factor: 3.346

Review 2.  Optogenetics enlightens neuroscience drug discovery.

Authors:  Chenchen Song; Thomas Knöpfel
Journal:  Nat Rev Drug Discov       Date:  2015-11-27       Impact factor: 84.694

Review 3.  Chemical probes and drug leads from advances in synthetic planning and methodology.

Authors:  Christopher J Gerry; Stuart L Schreiber
Journal:  Nat Rev Drug Discov       Date:  2018-04-13       Impact factor: 84.694

Review 4.  Multi-target drugs to address multiple checkpoints in complex inflammatory pathologies: evolutionary cues for novel "first-in-class" anti-inflammatory drug candidates: a reviewer's perspective.

Authors:  Geetha Mathew; M K Unnikrishnan
Journal:  Inflamm Res       Date:  2015-07-18       Impact factor: 4.575

5.  Identification of a dibenzocyclooctadiene lignan as a HIV-1 non-nucleoside reverse transcriptase inhibitor.

Authors:  Ying-Shan Han; Wei-Lie Xiao; Hongtao Xu; Victor G Kramer; Yudong Quan; Thibault Mesplède; Maureen Oliveira; Susan P Colby-Germinario; Han-Dong Sun; Mark A Wainberg
Journal:  Antivir Chem Chemother       Date:  2015-02

Review 6.  Let's get small (and smaller): Combining zebrafish and nanomedicine to advance neuroregenerative therapeutics.

Authors:  David T White; Meera T Saxena; Jeff S Mumm
Journal:  Adv Drug Deliv Rev       Date:  2019-02-12       Impact factor: 15.470

7.  Simultaneous elucidation of antibiotic mechanism of action and potency with high-throughput Fourier-transform infrared (FTIR) spectroscopy and machine learning.

Authors:  Bernardo Ribeiro da Cunha; Luís P Fonseca; Cecília R C Calado
Journal:  Appl Microbiol Biotechnol       Date:  2021-01-14       Impact factor: 4.813

Review 8.  Drug discovery and development for rare genetic disorders.

Authors:  Wei Sun; Wei Zheng; Anton Simeonov
Journal:  Am J Med Genet A       Date:  2017-07-21       Impact factor: 2.802

9.  Scaffold Ranking and Positional Scanning Identify Novel Neurite Outgrowth Promoters with Nanomolar Potency.

Authors:  Hassan Al-Ali; Ginamarie Debevec; Radleigh G Santos; Richard A Houghten; Jennifer C Davis; Adel Nefzi; Vance P Lemmon; John L Bixby; Marc A Giulianotti
Journal:  ACS Med Chem Lett       Date:  2018-09-24       Impact factor: 4.345

10.  Are bigger data sets better for machine learning? Fusing single-point and dual-event dose response data for Mycobacterium tuberculosis.

Authors:  Sean Ekins; Joel S Freundlich; Robert C Reynolds
Journal:  J Chem Inf Model       Date:  2014-07-17       Impact factor: 4.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.